Armistice Capital, LLC and Steven Boyd filed Amendment No. 4 to a beneficial ownership statement with the SEC on November 16, 2026, disclosing a combined holding of 13,750,000 American Depositary Shares of Autolus Therapeutics plc, representing 5.17% of the class.

Key Highlights

  • Aggregate beneficial ownership: Armistice Capital, LLC and Steven Boyd each reported 13,750,000 American Depositary Shares beneficially owned.
  • Percent of class: The 13,750,000 shares represent 5.17% of Autolus Therapeutics plc's outstanding class of American Depositary Shares.
  • Shared voting and dispositive power: Both reporting persons report 0 sole voting power and 0 sole dispositive power, with all 13,750,000 shares held on a shared basis.
  • Direct holder: The shares are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and investment advisory client of Armistice Capital.
  • Event date: The date of the event requiring this filing is September 30, 2026, according to the filing.
  • Amendment number: This filing is Amendment No. 4 to the original beneficial ownership statement.

Armistice Capital's Disclosed Position in Autolus Therapeutics

According to the filing, Armistice Capital, LLC, a Delaware-organized investment manager, and Steven Boyd, its managing member, together reported beneficial ownership of 13,750,000 American Depositary Shares of Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company headquartered at The Mediaworks, 191 Wood Lane, London, United Kingdom. Each American Depositary Share represents one ordinary share with a par value of $0.000042 per share, identified by CUSIP number 05280R100.

The filing states that Armistice Capital serves as investment manager to Armistice Capital Master Fund Ltd., the direct holder of the reported shares, and exercises voting and investment power over those securities pursuant to an Investment Management Agreement. As a result, both Armistice Capital and Mr. Boyd are each reported as beneficially owning the same 13,750,000 shares on a shared basis. The Master Fund, the filing notes, "specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital."

The filing further discloses that the Master Fund holds the right to receive dividends from, or the proceeds from the sale of, the reported securities. The reporting persons certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Armistice Capital, LLC and Steven Boyd filed Amendment No. 4 to their beneficial ownership statement, reporting shared ownership of 13,750,000 Autolus Therapeutics American Depositary Shares, equal to 5.17% of the class, with the event date of September 30, 2026.